Efalizumab/infliximab: CD8+ cutaneous T cell lymphoma (first report with efalizumab): 2 case reports

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1137, 2007-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efalizumab: Progression of cutaneous T-cell lymphoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1238, 2009-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Ciclosporin/efalizumab/infliximab/psoralens: Cutaneous squamous cell cancers in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1367, 2011-01 ,pp. : 12-13

Adis International

Access to resources Recommend Favorite

Efalizumab: T-cell clone proliferation: case report

By  

Reactions Weekly, Vol. 1, Iss. 1354, 2011-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

Efalizumab withdrawal: Rebound psoriasis, treated with infliximab then efalizumab: case report

By  

Reactions Weekly, Vol. 1, Iss. 1240, 2009-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Adalimumab/efalizumab/infliximab: Psoriasis: 5 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1210, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite